Quinn Deveraux

As one of their co-founders, Dr. Deveraux leads target identification and validation, as well as therapeutic lead selection, and oversees their pipeline development strategy. Before founding Inhibrx, he spent 10 years at the Genomics Institute of the Novartis Research Foundation (GNF). Dr. Deveraux led groups of Ph.D./M.D. level investigators in the conception and generation of novel target identification and validation platforms. He was a key member of the team that transitioned the first GNF therapeutic antibody from bench-top to clinical trials. His research on cell death at the Stanford Burnham Prebys Medical Discovery Institute has been highly cited. Dr. Deveraux received his Ph.D. in Biochemistry from the University of Utah School of Medicine.